Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting

被引:64
作者
Bayo-Puxan, Neus
Cascallo, Manel
Gros, Alena
Huch, Meritxell
Fillat, Cristina
Alemany, Ramon
机构
[1] IDIBELL Inst Catala Oncol, Translat Res Lab, Hop Llobregat, Barcelona 08907, Spain
[2] UPF, Ctr Gene Regulat, Barcelona, Spain
基金
英国惠康基金;
关键词
D O I
10.1099/vir.0.81889-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Liver tropism hampers systemic administration of adenovirus in gene therapy and virotherapy. In consequence, tumour targeting requires the combination of capsid modifications that abrogate liver transduction and redirect adenoviral vectors to tumour cells. Coxsackievirus and adenovirus; receptor (CAR), integrins and heparan sulfate glycosaminoglycans (HSG) are receptors involved in adenovirus type 5 (Ad5) entry into cells. The in vitro and in vivo properties of Ad5 vectors unable to bind CAR, integrins and HSG with and without Arg-Gly-Asp (RGD) inserted at the HI loop of the fiber were studied. As was previously observed with CAR-ablated vectors, CAR and integrin double binding-ablated vectors transduced hepatocytes less efficiently in vitro but not in vivo. On the contrary, the role of HSG on Ad5 infectivity was evident in vitro only when CAR binding was abrogated, but the shaft mutation that ablated HSG binding on the background of a normal capsid was sufficient to abrogate liver transduction in vivo. The insertion of amino acids RGD at the HI loop in a shaft-mutated fiber only partially rescued integrin-mediated infectivity. These results indicate that the shaft mutation precluded HSG binding and affected the structure of the fiber. The insertion of ligands at the hexon or protein IX may be required to benefit from the fiber shaft mutation-detargeting properties.
引用
收藏
页码:2487 / 2495
页数:9
相关论文
共 32 条
[1]   Blood clearance rates of adenovirus type 5 in mice [J].
Alemany, R ;
Suzuki, K ;
Curiel, DT .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :2605-2609
[2]   Replicative adenoviruses for cancer therapy [J].
Alemany, R ;
Balagué, C ;
Curiel, DT .
NATURE BIOTECHNOLOGY, 2000, 18 (07) :723-727
[3]   CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors [J].
Alemany, R ;
Curiel, DT .
GENE THERAPY, 2001, 8 (17) :1347-1353
[4]   Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 [J].
Bergelson, JM ;
Cunningham, JA ;
Droguett, G ;
KurtJones, EA ;
Krithivas, A ;
Hong, JS ;
Horwitz, MS ;
Crowell, RL ;
Finberg, RW .
SCIENCE, 1997, 275 (5304) :1320-1323
[5]   Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions [J].
Dechecchi, MC ;
Tamanini, A ;
Bonizzato, A ;
Cabrini, G .
VIROLOGY, 2000, 268 (02) :382-390
[6]   Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5 [J].
Dechecchi, MC ;
Melotti, P ;
Bonizzato, A ;
Santacatterina, M ;
Chilosi, M ;
Cabrini, G .
JOURNAL OF VIROLOGY, 2001, 75 (18) :8772-8780
[7]   An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism [J].
Dmitriev, I ;
Krasnykh, V ;
Miller, CR ;
Wang, MH ;
Kashentseva, E ;
Mikheeva, G ;
Belousova, N ;
Curiel, DT .
JOURNAL OF VIROLOGY, 1998, 72 (12) :9706-9713
[8]   A system for the propagation of adenoviral vectors with genetically modified receptor specificities [J].
Douglas, JT ;
Miller, CR ;
Kim, M ;
Dmitriev, I ;
Mikheeva, G ;
Krasnykh, V ;
Curiel, DT .
NATURE BIOTECHNOLOGY, 1999, 17 (05) :470-475
[9]   Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions [J].
Einfeld, DA ;
Schroeder, R ;
Roelvink, PW ;
Lizonova, A ;
King, CR ;
Kovesdi, I ;
Wickham, TJ .
JOURNAL OF VIROLOGY, 2001, 75 (23) :11284-11291
[10]   RETROVIRAL-MEDIATED GENE-TRANSFER OF HUMAN ORNITHINE TRANSCARBAMYLASE INTO PRIMARY HEPATOCYTES OF SPF AND SPF-ASH MICE [J].
GROMPE, M ;
JONES, SN ;
LOULSEGED, H ;
CASKEY, CT .
HUMAN GENE THERAPY, 1992, 3 (01) :35-44